<DOC>
	<DOC>NCT00101673</DOC>
	<brief_summary>This study was not conducted in the United States. The purpose of this study was to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels in people with type 2 diabetes who had not previously been treated with drug therapy to lower their blood sugar and whose blood sugar levels were in a specified range.</brief_summary>
	<brief_title>Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Blood glucose criteria must be met Not currently on drug therapy for type 2 diabetes Body mass index (BMI) in the range 2245 Pregnancy or lactation Type 1 diabetes Evidence of serious diabetic complications Evidence of serious cardiovascular conditions Laboratory value abnormalities as defined by the protocol Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>